Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
|Slideshows|September 25, 2018
Size Matters: Papillary Thyroid Carcinoma Recurrence
Author(s)Gregory M. Weiss, MD
Tumor size does indeed matter in the recurrence rate of papillary thyroid carcinoma, according to a new study.
Advertisement
Reference: Tran B, Roshan D, Abraham E, et al. The prognostic impact of tumor size in papillary thyroid carcinoma is modified by age. Thyroid. 2018;28:991-996.
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
4
DAPA-TRIO-HF: Dapagliflozin Improves HF Outcomes Regardless of Healthcare Setting
5